CoChat

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis

D’Addio, Francesca, Valderrama Vasquez, Alessandro, Ben Nasr, Moufida, Franek, Edward, Zhu, Dalong, Li, Lirong, Ning, Guang, Snarski, Emilian, Fiorina, Paolo · 2014 · Diabetes

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Type 1 diabetes (T1D) is one of the major autoimmune diseases affecting children and young adults worldwide. To date, the different immunotherapies tested have achieved insulin independence in <5% of treated individuals. Recently, a novel hematopoietic stem cell (HSC)–based strategy has been tested in individuals with new-onset T1D. The aim of this study was to determine the effects of autologous nonmyeloablative HSC transplantation in 65 individuals with new-onset T1D who were enrolled in two Chinese centers and one Polish center, pooled, and followed up for 48 months. A total of 59% of individuals with T1D achieved insulin independence within the first 6 months after receiving conditioning immunosuppression therapy (with antithymocyte globulin and cyclophosphamide) and a single infusion of autologous HSCs, and 32% remained insulin independent at the last time point of their follow-up. All treated subjects showed a decrease in HbA1c levels and an increase in C-peptide levels compared with pretreatment. Despite a complete immune system recovery (i.e., leukocyte count) after treatment, 52% of treated individuals experienced adverse effects. Our study suggests the following: 1) that remission of T1D is possible by combining HSC transplantation and immunosuppression; 2) that autologous nonmyeloablative HSC transplantation represents an effective treatment for selected individuals with T1D; and 3) that safer HSC-based therapeutic options are required.

Overview

Integrity signals

Registry

Crossref · 10.2337/db14-0295

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 162

Metadata

Authors
D’Addio, F., Valderrama Vasquez, A., Ben Nasr, M., Franek, E., Zhu, D., Li, L., Ning, G., Snarski, E., & Fiorina, P.
Affiliations
  • Boston Children's Hospital (US)
  • Transplant Medicine, IRCCS San Raffaele Hospital, Milan, Italy
  • Nephrology Division, Boston Children's Hospital, Harvard Medical School, Boston, MA
  • Ministry of Interior and Administration (PL)
  • Nanjing Drum Tower Hospital (CN)
  • Shanghai Jiao Tong University (CN)
  • Medical University of Warsaw (PL)
Corresponding author
Fiorina, Paolo
Venue
Diabetes
Published
2014-08-16
Volume
63
Issue
9
Pages
3041-3046
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2147402097
Cited by
160
References
26
Citations by year
2026: 5 · 2025: 5 · 2024: 11 · 2023: 6 · 2022: 13 · 2021: 21 · 2020: 13 · 2019: 4 · 2018: 18 · 2017: 17 · 2016: 24 · 2015: 19 · 2014: 4
FWCI
14.01
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
type 1 diabetes, autologous stem cell transplantation, nonmyeloablative conditioning, antithymocyte globulin, cyclophosphamide, insulin independence, remission, C-peptide, HbA1c, immune reconstitution, adverse effects
MeSH terms
Adolescent, Adult, C-Peptide, Child, Cyclophosphamide, Diabetes Mellitus, Type 1, Female, Humans, Immunosuppression Therapy, Insulin, Male, Remission Induction, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis. https://app.cochat.ai/papers/10.2337/db14-0295
The paper
D’Addio, F., Valderrama Vasquez, A., Ben Nasr, M., Franek, E., Zhu, D., Li, L., Ning, G., Snarski, E., & Fiorina, P. (2014). Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis. Diabetes. https://doi.org/10.2337/db14-0295

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.